Equities research analysts predict that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce sales of $130,000.00 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Aurinia Pharmaceuticals’ earnings, with estimates ranging from $30,000.00 to $350,000.00. Aurinia Pharmaceuticals posted sales of $30,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 333.3%. The business is scheduled to issue its next quarterly earnings results on Friday, November 3rd.

On average, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $130,000.00 for the current financial year, with estimates ranging from $120,000.00 to $1.07 million. For the next year, analysts forecast that the business will report sales of $16.48 million per share, with estimates ranging from $100,000.00 to $65.18 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. The business had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%.

Several research analysts recently issued reports on the company. Seaport Global Securities restated a “buy” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. Vetr upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 price objective for the company in a research report on Tuesday, September 19th. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Tuesday, August 15th. Cantor Fitzgerald set a $14.00 price objective on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $9.82.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp raised its holdings in Aurinia Pharmaceuticals by 1.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock valued at $502,000 after acquiring an additional 931 shares during the last quarter. Royal Bank of Canada raised its holdings in Aurinia Pharmaceuticals by 8.6% in the 2nd quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,341 shares during the last quarter. Nicholas Investment Partners LP raised its holdings in Aurinia Pharmaceuticals by 1.0% in the 2nd quarter. Nicholas Investment Partners LP now owns 254,084 shares of the biotechnology company’s stock valued at $1,557,000 after acquiring an additional 2,484 shares during the last quarter. UBS Group AG raised its holdings in Aurinia Pharmaceuticals by 13.6% in the 1st quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock valued at $824,000 after acquiring an additional 13,405 shares during the last quarter. Finally, FMR LLC raised its holdings in Aurinia Pharmaceuticals by 0.3% in the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after acquiring an additional 19,200 shares during the last quarter. Institutional investors own 27.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Aurinia Pharmaceuticals Inc (AUPH) Will Announce Quarterly Sales of $130,000.00” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/19/analysts-expect-aurinia-pharmaceuticals-inc-auph-will-announce-quarterly-sales-of-130000-00.html.

Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.51 on Thursday. Aurinia Pharmaceuticals has a 52-week low of $2.02 and a 52-week high of $10.54. The stock’s market capitalization is $543.49 million. The stock has a 50 day moving average price of $6.44 and a 200-day moving average price of $6.53.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.